Well is it just me? That looks like a rather significant development, no? For a full list of benefits of "Orphan Designation" see: orphan incentives
Also please note one of the benefits is: Ten years of market exclusivity
Authorised orphan medicines benefit from ten years of protection from market competition with similar medicines with similar indications once they are approved. This period of protection is extended by two years for medicines that also have complied with an agreed paediatric investigation plan.
News 
Market Data 
Discover 
